Aluminum Hydroxide Adjuvants Vaccine Linkers

Back to all technologies
Download as PDF
65683
Vaccines typically work by exposing the body to an antigen, which is either a weakened form of a microorganism or a toxin that it creates. This exposure stimulates an immune system response that lets the body recognize the pathogen so that it can more easily recognize and destroy it in the future. Sometimes, the proteins used in the vaccine are bound to an adjuvant (commonly aluminum hydroxide), which acts as an irritant to enhance the immune response to the antigen while reducing the amount of foreign material that must be injected. To attach the aluminum hydroxide to the protein, a phosphate group is first attached to the protein. Phosphate groups have a high electrostatic affinity for aluminum hydroxide, so they readily bond to each other. However, current techniques for attaching the phosphate group to a protein have the unintended effect of changing the structure of the protein.

Purdue University researchers have developed a simple chemical reagent that attaches a phosphate group to specific sites on the protein, but does not change the overall structure. This method can work with a wide variety of antigens and could lead to vaccines that are more effective for many pathogens.

Advantages:
-Does not modify protein structure
-Works with many varieties of antigens
-Uses adjuvant with excellent safety record

Potential Applications:
-Medical/Healthcare
-Pharmaceutical industry
-Vaccines
Jun 8, 2018
DIV-Patent
United States
10,159,750
Dec 25, 2018

Aug 6, 2014
NATL-Patent
United States
10,010,616
Jul 3, 2018

Jan 27, 2012
PCT-Patent
WO
(None)
(None)

Jan 28, 2011
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org